Fundamental Analysis of Eiger Biopharmaceuticals Inc - Growth / Value Index


EIGR - Valuation Highlights

Valuation Analysis

   Tsr Value Index - Very Poor Score of 5.00
   Price to Book Ratio of 35.57 suggesting that it is very expensive
   Book Value in last 3 years is trending down
   Book value is negative
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -8.52 -0.0295 -19.09 %
Price to Book 35.57 -0.177 -507.89 % -0.0462
Price to Sales 40.49 0.174 -1.97 %
Enterprise Value to EBITDA Multiple -0.261 -0.227 76.65 %


EIGR - Profitability Highlights

Profitability Analysis

   Piotroski F Score - Stable Value of 4.0
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Tsr Profitability Index - Very Poor Score of 6.58
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
   Negative Net Margin MRQ
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity -417.47 0 0 % 0
Return On Asset -97.05 -223.17 -177.04 % -34.65
Net Profit Margin -475.26 -590.80 17.68 % -353.77
Operating Profit Margin -455.12 -570.32 17.08 % -331.69
EBITDA Margin -445.41 -549.58 19.74 % -311.54


Highlights
Market Cap2552.12 K
Enterprise Value18315.12 K
Price/Book TTM35.57
Outstanding Share1479.49 K
Float/ Outstanding Share85.97%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score4.00
Altman Z Score-25.45
Sloan Ratio-0.098
Peter Lynch Fair Value0


EIGR - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Tsr Growth Index - Very Poor Score of 6.31
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 15773.00 K 8.77 % 18.51 %
Gross Profit 15129.00 K 23.62 % 19.65 %
EBITDA -70254.00 K 12.70 % 30.01 %
Net Profit -74963.00 K 10.47 % 25.38 %
EPS -0.202 16.03 % NA


EIGR - Stability Highlights

Stability Analysis

   Paid More Than 50% of Debt, Heading towards debt free
   Debt to equity ratio has decreased and is lowest in last five years
   Tsr Stability Index - Very Poor Score of 5.00
   Altman Z Score of -25.45 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -15.47
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio -2.85 -239.16 % -2.85
Cash Ratio 0.477 -53.51 %
Quick Ratio 0.681 -85.08 % 0.681
Shareholders Equity -37.24 -180.88 %
Debt to EBITDA -0.511 58.33 %


Historical Valuation Ratios of Eiger Biopharmaceuticals Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Eiger Biopharmaceuticals Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Eiger Biopharmaceuticals Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Eiger Biopharmaceuticals Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)